<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LAMIVUDINE" rxcui="68244">
<ATC code="J05AF05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to inhibition of the phosphorylation reaction at the origin of the active metabolites </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
</INTERACTIONS>
